SRI, Spyglass to Commercialize Underwater Mass Spec Technology | GenomeWeb

NEW YORK (GenomeWeb News) – SRI International and Spyglass Technologies today announced an exclusive licensing deal to commercialize SRI's underwater mass spectrometry technology.

The agreement calls for St. Petersburg, Fla.-based Spyglass to apply SRI's in situ membrane introduction mass spec (MIMS) technology to "a broad range of commercial, research, and government applications." Additionally, Spyglass will bundle the MIMS device with other underwater sensors, and the partners will continue collaborating on applications of the technology for other markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.